To improve the tumor-homing ability of TRAIL, directional molecules, such as antibody fragments and small peptides recognizing tumor-associated antigens, were fused to TRAIL (Möller et al., 2014; Tao et al., 2017). The gene discussed is TNFSF10; the disease is neoplasm.